October 2, 2023 PDF Version J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Technology Officer BOSTON–(BUSINESS WIRE)–Oct. 2, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
September 3, 2024 Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology BOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to treat a range of solid tumors designed to preserve organ function, today announced that it will host a virtual urologic…
2024-05-23 Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024 BOSTON, May 23, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that it will…
2024-05-30 Aura Biosciences to Participate in the Jefferies Global Healthcare Conference BOSTON, May 30, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will present at the Jefferies…
May 12, 2023 PDF Version BOSTON–(BUSINESS WIRE)–May 12, 2023– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023, at 2:00…
Aura Biosciences to Participate in Upcoming Investor ConferencesFebruary 26, 2024PDF Version BOSTON–(BUSINESS WIRE)–Feb. 26, 2024– Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: 44th Annual TD…
